Costa Georgantas, Jaume Banus, Roger Hullin, Jonas Richiardi
{"title":"Systematic Estimation of Treatment Effect on Hospitalization Risk as a Drug Repurposing Screening Method.","authors":"Costa Georgantas, Jaume Banus, Roger Hullin, Jonas Richiardi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Drug repurposing (DR) intends to identify new uses for approved medications outside their original indication. Computational methods for finding DR candidates usually rely on prior biological and chemical information on a specific drug or target but rarely utilize real-world observations. In this work, we propose a simple and effective systematic screening approach to measure medication impact on hospitalization risk based on large-scale observational data. We use common classification systems to group drugs and diseases into broader functional categories and test for non-zero effects in each drug-disease category pair. Treatment effects on the hospitalization risk of an individual disease are obtained by combining widely used methods for causal inference and time-to-event modelling. 6468 drug-disease pairs were tested using data from the UK Biobank, focusing on cardiovascular, metabolic, and respiratory diseases. We determined key parameters to reduce the number of spurious correlations and identified 7 statistically significant associations of reduced hospitalization risk after correcting for multiple testing. Some of these associations were already reported in other studies, including new potential applications for cardioselective beta-blockers and thiazides. We also found evidence for proton pump inhibitor side effects and multiple possible associations for anti-diabetic drugs. Our work demonstrates the applicability of the present screening approach and the utility of real-world data for identifying potential DR candidates.</p>","PeriodicalId":34954,"journal":{"name":"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing","volume":"29","pages":"232-246"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Computer Science","Score":null,"Total":0}
引用次数: 0
Abstract
Drug repurposing (DR) intends to identify new uses for approved medications outside their original indication. Computational methods for finding DR candidates usually rely on prior biological and chemical information on a specific drug or target but rarely utilize real-world observations. In this work, we propose a simple and effective systematic screening approach to measure medication impact on hospitalization risk based on large-scale observational data. We use common classification systems to group drugs and diseases into broader functional categories and test for non-zero effects in each drug-disease category pair. Treatment effects on the hospitalization risk of an individual disease are obtained by combining widely used methods for causal inference and time-to-event modelling. 6468 drug-disease pairs were tested using data from the UK Biobank, focusing on cardiovascular, metabolic, and respiratory diseases. We determined key parameters to reduce the number of spurious correlations and identified 7 statistically significant associations of reduced hospitalization risk after correcting for multiple testing. Some of these associations were already reported in other studies, including new potential applications for cardioselective beta-blockers and thiazides. We also found evidence for proton pump inhibitor side effects and multiple possible associations for anti-diabetic drugs. Our work demonstrates the applicability of the present screening approach and the utility of real-world data for identifying potential DR candidates.
药物再利用(DR)旨在为已批准的药物确定其原始适应症之外的新用途。寻找 DR 候选药物的计算方法通常依赖于特定药物或靶点的先前生物和化学信息,但很少利用真实世界的观察结果。在这项工作中,我们提出了一种简单有效的系统筛选方法,基于大规模观察数据来衡量药物对住院风险的影响。我们使用常见的分类系统将药物和疾病归入更广泛的功能类别,并检验每个药物-疾病类别对的非零效应。通过结合广泛使用的因果推断和时间到事件建模方法,得出治疗对单个疾病住院风险的影响。我们利用英国生物库的数据对 6468 对药物-疾病配对进行了测试,重点关注心血管、代谢和呼吸系统疾病。我们确定了减少虚假相关性的关键参数,并在校正多重检验后确定了 7 种具有统计学意义的降低住院风险的相关性。其中一些关联在其他研究中已有报道,包括心脏选择性β受体阻滞剂和噻嗪类药物的新潜在应用。我们还发现了质子泵抑制剂副作用的证据以及抗糖尿病药物的多种可能关联。我们的工作证明了目前筛选方法的适用性以及真实世界数据在确定潜在 DR 候选药物方面的实用性。